Research ExplorerPublicationsBaseline characteristics of patients in the Reduction of Eve...

Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF)

Standard

Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF). / McMurray, John J V; Anand, Inder S; Diaz, Rafael; Maggioni, Aldo P; O'Connor, Christopher; Pfeffer, Marc A; Solomon, Scott D; Tendera, Michal; van Veldhuisen, Dirk J; Albizem, Moetaz; Cheng, Sunfa; Scarlata, Debra; Swedberg, Karl; Young, James B; RED-HF Committees.

In: EUR J HEART FAIL, Vol. 15, No. 3, 03.2013, p. 334-341.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

McMurray, JJV, Anand, IS, Diaz, R, Maggioni, AP, O'Connor, C, Pfeffer, MA, Solomon, SD, Tendera, M, van Veldhuisen, DJ, Albizem, M, Cheng, S, Scarlata, D, Swedberg, K, Young, JB & RED-HF Committees 2013, 'Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF)', EUR J HEART FAIL, vol. 15, no. 3, pp. 334-341. https://doi.org/10.1093/eurjhf/hfs204

APA

McMurray, J. J. V., Anand, I. S., Diaz, R., Maggioni, A. P., O'Connor, C., Pfeffer, M. A., Solomon, S. D., Tendera, M., van Veldhuisen, D. J., Albizem, M., Cheng, S., Scarlata, D., Swedberg, K., Young, J. B., & RED-HF Committees (2013). Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF). EUR J HEART FAIL, 15(3), 334-341. https://doi.org/10.1093/eurjhf/hfs204

Vancouver

McMurray JJV, Anand IS, Diaz R, Maggioni AP, O'Connor C, Pfeffer MA et al. Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF). EUR J HEART FAIL. 2013 Mar;15(3):334-341. https://doi.org/10.1093/eurjhf/hfs204

Bibtex

@article{55fc843a17d74378bed3e6ef10f9eee4,
title = "Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF)",
abstract = "AIMS: This report describes the baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF) which is testing the hypothesis that anaemia correction with darbepoetin alfa will reduce the composite endpoint of death from any cause or hospital admission for worsening heart failure, and improve other outcomes.METHODS AND RESULTS: Key demographic, clinical, and laboratory findings, along with baseline treatment, are reported and compared with those of patients in other recent clinical trials in heart failure. Compared with other recent trials, RED-HF enrolled more elderly [mean age 70 (SD 11.4) years], female (41%), and black (9%) patients. RED-HF patients more often had diabetes (46%) and renal impairment (72% had an estimated glomerular filtration rate < 60 mL/min/1.73 m2). Patients in RED-HF had heart failure of longer duration [5.3 (5.4) years], worse NYHA class (35% II, 63% III, and 2% IV), and more signs of congestion. Mean EF was 30% (6.8%). RED-HF patients were well treated at randomization, and pharmacological therapy at baseline was broadly similar to that of other recent trials, taking account of study-specific inclusion/exclusion criteria. Median (interquartile range) haemoglobin at baseline was 112 (106-117) g/L.CONCLUSION: The anaemic patients enrolled in RED-HF were older, moderately to markedly symptomatic, and had extensive co-morbidity.",
keywords = "Aged, Aged, 80 and over, Anemia/complications, Cause of Death, Clinical Trials as Topic/statistics & numerical data, Comorbidity, Darbepoetin alfa, Demography/statistics & numerical data, Double-Blind Method, Erythropoietin/analogs & derivatives, Female, Heart Failure/complications, Hematinics/therapeutic use, Hospitalization/statistics & numerical data, Humans, Male, Middle Aged, Severity of Illness Index, Treatment Outcome",
author = "McMurray, {John J V} and Anand, {Inder S} and Rafael Diaz and Maggioni, {Aldo P} and Christopher O'Connor and Pfeffer, {Marc A} and Solomon, {Scott D} and Michal Tendera and {van Veldhuisen}, {Dirk J} and Moetaz Albizem and Sunfa Cheng and Debra Scarlata and Karl Swedberg and Young, {James B} and {RED-HF Committees} and Kai M{\"u}llerleile",
year = "2013",
month = mar,
doi = "10.1093/eurjhf/hfs204",
language = "English",
volume = "15",
pages = "334--341",
journal = "EUR J HEART FAIL",
issn = "1388-9842",
publisher = "Oxford University Press",
number = "3",

}

RIS

TY - JOUR

T1 - Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF)

AU - McMurray, John J V

AU - Anand, Inder S

AU - Diaz, Rafael

AU - Maggioni, Aldo P

AU - O'Connor, Christopher

AU - Pfeffer, Marc A

AU - Solomon, Scott D

AU - Tendera, Michal

AU - van Veldhuisen, Dirk J

AU - Albizem, Moetaz

AU - Cheng, Sunfa

AU - Scarlata, Debra

AU - Swedberg, Karl

AU - Young, James B

AU - RED-HF Committees

AU - Müllerleile, Kai

PY - 2013/3

Y1 - 2013/3

N2 - AIMS: This report describes the baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF) which is testing the hypothesis that anaemia correction with darbepoetin alfa will reduce the composite endpoint of death from any cause or hospital admission for worsening heart failure, and improve other outcomes.METHODS AND RESULTS: Key demographic, clinical, and laboratory findings, along with baseline treatment, are reported and compared with those of patients in other recent clinical trials in heart failure. Compared with other recent trials, RED-HF enrolled more elderly [mean age 70 (SD 11.4) years], female (41%), and black (9%) patients. RED-HF patients more often had diabetes (46%) and renal impairment (72% had an estimated glomerular filtration rate < 60 mL/min/1.73 m2). Patients in RED-HF had heart failure of longer duration [5.3 (5.4) years], worse NYHA class (35% II, 63% III, and 2% IV), and more signs of congestion. Mean EF was 30% (6.8%). RED-HF patients were well treated at randomization, and pharmacological therapy at baseline was broadly similar to that of other recent trials, taking account of study-specific inclusion/exclusion criteria. Median (interquartile range) haemoglobin at baseline was 112 (106-117) g/L.CONCLUSION: The anaemic patients enrolled in RED-HF were older, moderately to markedly symptomatic, and had extensive co-morbidity.

AB - AIMS: This report describes the baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF) which is testing the hypothesis that anaemia correction with darbepoetin alfa will reduce the composite endpoint of death from any cause or hospital admission for worsening heart failure, and improve other outcomes.METHODS AND RESULTS: Key demographic, clinical, and laboratory findings, along with baseline treatment, are reported and compared with those of patients in other recent clinical trials in heart failure. Compared with other recent trials, RED-HF enrolled more elderly [mean age 70 (SD 11.4) years], female (41%), and black (9%) patients. RED-HF patients more often had diabetes (46%) and renal impairment (72% had an estimated glomerular filtration rate < 60 mL/min/1.73 m2). Patients in RED-HF had heart failure of longer duration [5.3 (5.4) years], worse NYHA class (35% II, 63% III, and 2% IV), and more signs of congestion. Mean EF was 30% (6.8%). RED-HF patients were well treated at randomization, and pharmacological therapy at baseline was broadly similar to that of other recent trials, taking account of study-specific inclusion/exclusion criteria. Median (interquartile range) haemoglobin at baseline was 112 (106-117) g/L.CONCLUSION: The anaemic patients enrolled in RED-HF were older, moderately to markedly symptomatic, and had extensive co-morbidity.

KW - Aged

KW - Aged, 80 and over

KW - Anemia/complications

KW - Cause of Death

KW - Clinical Trials as Topic/statistics & numerical data

KW - Comorbidity

KW - Darbepoetin alfa

KW - Demography/statistics & numerical data

KW - Double-Blind Method

KW - Erythropoietin/analogs & derivatives

KW - Female

KW - Heart Failure/complications

KW - Hematinics/therapeutic use

KW - Hospitalization/statistics & numerical data

KW - Humans

KW - Male

KW - Middle Aged

KW - Severity of Illness Index

KW - Treatment Outcome

U2 - 10.1093/eurjhf/hfs204

DO - 10.1093/eurjhf/hfs204

M3 - SCORING: Journal article

C2 - 23329651

VL - 15

SP - 334

EP - 341

JO - EUR J HEART FAIL

JF - EUR J HEART FAIL

SN - 1388-9842

IS - 3

ER -